Guardant Health director Manuel Hidalgo Medina sells $279k in stock

Manuel Hidalgo Medina, a director at Guardant Health, Inc. (NASDAQ:GH), recently sold shares worth approximately $279,201, according to a Form 4 filing with the Securities and Exchange Commission dated August 5, 2026. The sales occurred at prices ranging from $163.945 to $164.6051 per share. Concurrently, Mr. Medina acquired common stock valued at $30,922 through the exercise of stock options, at a price of $32.55 per share. The director’s sale comes as the stock trades near its 52-week high of $176.58, following a remarkable 266% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. An InvestingPro tip notes that stock price movements are quite volatile, with 11 additional exclusive tips available to subscribers.

On August 5, 2026, Mr. Medina acquired 950 shares of common stock at a price of $32.55 each, stemming from the exercise of stock options. Subsequently, he disposed of a total of 1,700 shares of common stock. These disposals included 950 shares sold at $163.945 per share and an additional 750 shares sold at $164.6051 per share. Following these transactions, Mr. Medina directly holds 4,556 shares of Guardant Health common stock.

The acquisition of 950 shares resulted from the exercise of a stock option with an exercise price of $32.55. This option was granted on July 17, 2024, and vests over a four-year period. Twenty-five percent of the shares subject to this award vested on July 17, 2025, with the remaining 75% vesting monthly for the three-year period thereafter. After this exercise, Mr. Medina beneficially owns 12,079 derivative securities.

The filing was signed by John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina, on August 6, 2026. For deeper insights into Guardant Health’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.

In other recent news, Guardant Health reported impressive second-quarter results with revenue reaching $335 million, marking a 44% increase. This performance exceeded expectations and led the company to raise its guidance for the year. Analysts have responded positively, with Stifel raising its price target to $180 and maintaining a Buy rating. TD Cowen also increased its price target to $210, citing strong volume growth for Shield and G360 products, contributing to a 7% sales upside. Mizuho followed suit by raising its target to $200, highlighting a significant volume beat with 66,000 Guardant Shield tests conducted. Additionally, BTIG adjusted its price target to $195, noting the 63% year-over-year growth in core oncology volumes. These developments reflect a robust quarter for Guardant Health, with substantial growth in both Shield and oncology volumes.